✦ LIBER ✦

A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B

✍ Scribed by Su Rin Shin; Byung Chul Yoo; Moon Seok Choi; Dong Ho Lee; Soon Mi Song; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik

Publisher: Springer-Verlag
Year: 2011
Tongue: English
Weight: 243 KB
Volume: 5
Category: Article
ISSN: 1936-0533
DOI: 10.1007/s12072-010-9238-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Entecavir treatment for chronic hepatiti

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

✍ Roeland Zoutendijk; Jurriën G. P. Reijnders; Ashley Brown; Fabien Zoulim; David 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV

Corrections: Entecavir treatment for chr

Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

In the August 2011 issue of HEPATOLOGY, in the article entitled ''Carcinogen-induced hepatic tumors in KLF6þ/À mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation'' (volume 54, pages 522-531), Dr.

Efficacy and safety of entecavir compare

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

✍ Guangbi Yao; Chengwei Chen; Weilun Lu; Hong Ren; Deming Tan; Yuming Wang; Daozhe 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 223 KB

Efficacy and safety of entecavir compare

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

✍ Guangbi Yao; Chengwei Chen; Weilun Lu; Hong Ren; Deming Tan; Yuming Wang; Daozhe 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 89 KB

De novo combination of lamivudine and ad

De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients

✍ Li-Chun Wang; En-Qiang Chen; Jing Cao; Li Liu; Li Zheng; Da-Jiang Li; Lu Xu; Xue 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 243 KB

A phase III study of the safety and effi

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results

✍ Yves Benhamou; Nezam H. Afdhal; David R. Nelson; Mitchell L. Shiffman; Deanine G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 452 KB 👁 2 views

Pegylated interferon (peg-IFN) and ribavirin (RBV) are effective in eradicating the hepatitis C virus in more than half of patients. However, anemia arising from RBV-induced hemolysis can prompt dose reductions and lower sustained virologic response (SVR) rates. In early clinical trials, Viramidine